Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.
No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.
Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/. a.s.s.domling@rug.nl.
Alexander
A
Dömling
Tad A
TA
Holak
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D008958:Models, Molecular; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*
D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
antibodies; cancer immunotherapy; immune checkpoint; programmed death 1; protein-protein interactions